INDUSTRY AND ACADEMIA COLLADORATE IN ANTI-TB VACCINE DEVELOPMENT

摘要

Dalton Pharma Services and the University of Guelph are collaborating on the development of an anti-tuberculosis (TB) vaccine. Initiation of the program was made possible through government funding directed at applied research. The vaccine will be jointly developed at the University of Guelph and Dalton under the direction of professor Mario A. Monteiro, who is a world leader in microbial polysaccharide discovery and the development of polysaccharide-based vaccines. Dalton will scale up and manufacture the conjugate vaccine under GLP for proof of concept studies in an animal model.